LEXINGTON, Mass., Sept. 4, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate at the following conferences:The H.C. Wainwright 26th Annual Global Investment Conference being held September 9 – 11, 2024. Presentation details are as follows:Format: Company PresentationDate: Wednesday, ...